HOME >> MEDICINE >> NEWS
Institute of Medicine elects Gladstone Director Warner Greene

The Institute of Medicine of the National Academies today announced that it has elected Gladstone Institute of Virology and Immunology Director and Senior Investigator Warner C. Greene, MD, PhD, to its membership.

"We are very proud of this well deserved honor for Dr. Greene," said fellow IOM member Robert W. Mahley, MD, PhD, president, The J. David Gladstone Institutes. "His research has contributed enormously to our understanding of HIV/AIDS and a great many other important immunology issues of our time."

Greene, a professor of medicine, microbiology and immunology at the University of California, San Francisco and co-director of the federally funded UCSF-Gladstone Center for AIDS Research (CFAR), focuses on studies of the molecular basis for HIV and HTLV-I retroviral pathogenesis. He also studies the biochemical mechanisms underlying the regulation and action of the NF-kB/Rel family of eukaryotic transcription factors. The author of more than 300 scientific papers, he has been named a councilor of the American Association of Physicians and has been honored by outstanding investigator awards from the American Federation for Clinical Research and the American College of Rheumatology, among many others.

The Institute of Medicine (IOM) is a nonprofit organization created to provide science-based advice on matters of biomedical science, medicine, and health. An honorific membership organization chartered in 1970 as a component of the National Academy of Sciences, it works outside the framework of government to ensure scientifically informed analysis and independent guidance. Its mission is to serve as adviser to the nation to improve health.

Greene has been elected as one of 64 new members, raising the IOM's total active membership to 1,461. In addition, the Institute has honored five individuals by election to foreign associate membership, bringing the total members in that category to 79. With another 62 members holding emeritus stat
'"/>

Contact: John Watson
jwatson@gladstone.ucsf.edu
415-734-2019
Gladstone Institutes
24-Oct-2005


Page: 1 2

Related medicine news :

1. Worcester Polytechnic Institute to host national forum on locating first responders inside buildings
2. Wesley Research Institute study targets pharmacists to help diabetes sufferers
3. CIRM awards $3.79 million to Burnham Institute
4. Institute of Medicine Advisory: Public health physicians
5. OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
6. OHSU Cancer Institute, VA researchers find way to identify which men need a second biopsy
7. OHSU Cancer Institute researcher identifies protein marker for prostate cancer survival
8. Dr. Eli Peli of Schepens Eye Research Institute elected SPIE fellow
9. AGA Institute takes leadership role in exploring obesity and its complications
10. Kavli Institutes Journalist Workshop, June 13, at Cornell
11. National Academy of Sciences Institute of Medicine report calls for more dairy foods at school

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Institute Medicine elects Gladstone Director Warner Greene

(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay News) -- ... some of the changes brought about by the disorder ... New research has found that people with diabetes who ... risk of having a severe low blood sugar (hypoglycemia) ... people with diabetes who aren,t depressed. "Depression ...
(Date:5/21/2013)... long been known for their health benefits, and ... like anti-cancer drugs are delivered to specific tumor ... how to create nanoparticles using natural lipids derived ... them as drug delivery vehicles. UofL scientists Huang-Ge ... team today (May 21, 2013), published their findings ...
(Date:5/21/2013)... Schaumburg, IL (PRWEB) May 21, 2013 ... administration for large, medium, and small organizations, will be ... featuring an experts team from Findley Davies. The presentation ... is up-to-date and in compliance with new Health Care ... ideas to engage employees. , “Benefit Express regularly ...
(Date:5/21/2013)... May 21, 2013 Dr. Francine Kaufman , ... she used with her patients in the 1980s: It weighed several ... For the most part, it could only be used in the ... years since then, and the advantages are greater as well. The ... outside of the body, often on a belt or a pocket. ...
(Date:5/21/2013)... 21, 2013 A plastic surgery ... for plastic surgery SEO services following an Internet ... to name the “Best Plastic Surgery SEO Services”. ... outcome was predictable. Well-known in the plastic surgery ... patients than any other selection based on superior ...
Breaking Medicine News(10 mins):Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 2Health News:Depression May Raise Low Blood Sugar Risk in Diabetics 3Health News:UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery 2Health News:Benefit Express to Host Workplace Wellness Webinar 2Health News:Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives 2Health News:Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives 3Health News:Kaufman Shows People With Diabetes How to Use New Technology to Improve Their Lives 4Health News:JD Media Surge's CosmeticSurgeonsOnline.com Voted #1 Source for Plastic Surgery SEO 2
(Date:5/21/2013)... WESTBURY, N.Y. , May 21, 2013  Vasomedical, Inc. ... specializing in the design, manufacture and sale of medical devices ... today that Dr. Jun Ma , President ... Annual Marcum LLP MicroCap Conference on Thursday, May 30, 2013 ... Grand Hyatt Hotel. The Company,s presentation is ...
(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Technologies for Optical Coherence Tomography (OCT) ... STUDY OBJECTIVES   ... study is to offer synopsis of the ...
(Date:5/21/2013)... Fla. , May 21, 2013  Janssen ... safety results from the global Phase 3 PROMISE ... inhibitor simeprevir (TMC435) led to sustained virologic response ... in 79 percent of treatment-experienced genotype 1 chronic ... including all stages of liver fibrosis, when administered ...
Breaking Medicine Technology:Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
Cached News: